Menu Close

ILC 2023 Posters

The poster PDFs provided here have been shared with the consent of the authors. This collection includes poster PDFs for 29 out of 50 posters, depending on which authors granted permission for their poster PDFs to be published.

1Gitte ZelsOverview of patients with invasive lobular breast carcinoma included in the post-mortem tissue donation program, UPTIDERClinical
2Qian ZhaoClinical Characteristics and Outcomes of Invasive Lobular CarcinomaClinical
3Jasmine TimbresRisk factors pre-disposing to LCIS and ILCClinical
4Josephine Van CauwenbergeReporting on invasive lobular carcinoma in clinical drug trials and trials investigating gene expression profiles and molecular screening programs – a systematic reviewClinical
5Siobhan FreeneyEnhancing Knowledge and Research in Europe for Invasive Lobular Breast Cancer: Unique Challenges across European CountriesClinical
6Helen Coulthard“they… kept saying there’s nothing there”: British Women’s accounts of delayed lobular breast cancer diagnosisDiagnosis
7Laurie HutchesonIndividuals with Invasive Lobular Carcinoma (ILC) Raise their Voices about ILC and SurgeryDiagnosis
8Luca NicosiaContrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the management of breast lobular neoplasia: a new scenario in facing the diagnosis of an insidious diseaseDiagnosis
10Annapurna GuptaDownregulation of Arginosuccinate synthase 1 confers Tamoxifen Resistance in Invasive Lobular Breast CancerTreatment
11Bernadette Heemskerk-GerritsenThe effect of (neo)adjuvant chemotherapy on long-term survival outcomes in Invasive Lobular Breast Cancer Patients treated with endocrine therapy: a retrospective cohort studyTreatment
13Christina GerschCharacterization of Resistance to CDK4/6 Inhibitors and Endocrine Therapy in Invasive Lobular Breast Cancers Cell LinesTreatment
16Melinda SandersHigh prevalence of HER2-low among ILC with residual disease following neoadjuvant therapy provides therapeutic opportunities with HER2-antibody-drug conjugatesTreatment
17William YangE-cadherin loss imparts mitotic vulnerabilities rendering breast cancer cells synthetic lethal to crizotinib and up-regulation of Src signalling reverses this effectTreatment
20Francesca MagnoniComparison of long-term outcome between high risk lobular versus ductal breast cancer: a propensity score matched studyPrognosis
21Rebecca RigginsGlutamate metabolic enzymes associate with increased tumor size in black women with invasive lobular breast cancer: a single-institution studyPrognosis
22Simran SandhuRacial Disparities in Survival in Lobular Breast CancerPrognosis
23Baylee PorterGlucocorticoid receptor activation inhibits tumor cell growth while increasing metastatic characteristics in models of invasive lobular breast cancerMetastasis
24Bernadette Heemskerk-GerritsenLocalization of metastatic disease in patients with a history of lobular carcinoma of the breastMetastasis
27Andi CaniSerial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importanceBiomarker
28Chinasa A UfonduAssessing the Effect of E-cadherin loss on Estrogen Receptor activity in Human Mammary Epithelial Cell ModelsBiomarker
30Luyu JiaMutating E-cadherin in Rats to Model Lobular Breast CancerBiomarker
31Madeleine ShacklefordWNT4 regulates cellular metabolism via intracellular activity at the mitochondria in invasive lobular carcinoma cellsBiomarker
32Maggie MusickE-cadherin suppression supports transcriptional programs of
lineage plasticity in early ILC tumorigenesis
36Matteo SerraSpatially resolved analysis of tumor microenvironment revealed biologically driven subgroups with distinct clinical outcome in invasive lobular carcinomaTME
37Emmanuelle mouret-fourmeClinical Characteristics of Lobular Breast Carcinoma in CDH1 genetic predisposition. Experience from the Institut CurieGenetics
40Rita Canas-MarquesAberrant E-cadherin (E-cad) Expression in Lobular Carcinoma in Situ (LCIS): A Comprehensive Evaluation of N-terminal, Extracellular, and C-terminal E-cadherin DomainsGenetics
41Jing YuLobular-like invasive mammary carcinoma: Is this a ductal cancer, lobular cancer, or a distinct entity?Genetics
44Sanghoon LeeChromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomasEpigenomics
48Sarah NashTranscriptomic and immune heterogeneity underpin the biology of pleomorphic invasive lobular breast cancerMultiomics